Skip to main content
Premium Trial:

Request an Annual Quote

Germany's Mosaiques Collaborating with FDA on Drug Toxicity Biomarkers

NEW YORK (GenomeWeb News) – German firm Mosaiques Diagnostics and Therapeutics has inked a contract with the US Food and Drug Administration to collaborate on the discovery and validation of biomarkers for assessing drug toxicity.

Under the partnership, the FDA will provide information about drugs, expected toxicities, and animal studies. Mosaiques will contribute its proteome analysis expertise, particularly in sample preparation of urine and capillary electrophoresis coupled mass spectrometry.

"We are aiming to reduce or even prevent adverse effects of drugs by implementing our technology in preclinical testing," Mosaiques Founder and CSO Harald Mischak, said in a statement. "This agreement with the FDA underlines the potential of the protein pattern technology for modern medicine and appropriate treatment."

Further terms of the collaboration were not disclosed.

The Scan

Another Resignation

According to the Wall Street Journal, a third advisory panel member has resigned following the US Food and Drug Administration's approval of an Alzheimer's disease drug.

Novavax Finds Its Vaccine Effective

Reuters reports Novavax's SARS-CoV-2 vaccine is more than 90 percent effective in preventing COVID-19.

Can't Be Used

The US Food and Drug Administration says millions of vaccine doses made at an embattled manufacturing facility cannot be used, the New York Times reports.

PLOS Papers on Frozen Shoulder GWAS, Epstein-Barr Effects on Immune Cell Epigenetics, More

In PLOS this week: genome-wide association study of frozen shoulder, epigenetic patterns of Epstein-Barr-infected B lymphocyte cells, and more.